December - 2022

Dec 28, 2022

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients. Debbie S Deben , Rob H Creemers, Arjan J van Adrichem, Roosmarie Drent, Audrey H H Merry, Mathie P G Leers, Adriaan A van Bodegraven, Dennis R Wong Published in Sep 2022, Scientific reports Abstract The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treat

IBDENC ENC

Dec 27, 2022

Impact of an exercise program in children with inflammatory bowel disease in remission

Ivana Trivić , Sara Sila, Zrinjka Mišak, Tena Niseteo , Ana Tripalo Batoš , Iva Hojsak , Sanja Kolaček Published in Nov 2022, Pediatric research. Abstract Background The aim of our study was to investigate the impact of a structured exercise program on bone mineral density (BMD) and body composition parameters in children and adolescents with IBD in remission. Methods Patients were recruited to participate in a 6-month exercise program. Total body less head (TLBH) dual energy

IBDENC ENC

Dec 24, 2022

Inflammatory bowel disease-specific findings are common morphological changes

Inflammatory bowel disease-specific findings are common morphological changes in the ileal pouch with ulcerative colitis. Kenichiro Toritani, Hideaki Kimura, Masako Otani, Hironori Fukuoka, Reiko Kunisaki, Jun Watanabe, Atsushi Ishibe, Toshihiro Misumi, Yoshiaki Inayama, Itaru Endo Published in Nov 2022, Scientific reports Abstract Why inflammation is common in ileal pouches with ulcerative colitis (UC) is unclear. We therefore clarified the morphological changes in pouches a

IBDENC ENC

Dec 24, 2022

Diagnostic yield and technical performance of novel motorized spiral enteroscopy

Diagnostic yield and technical performance of novel motorized spiral enteroscopy compared to single-balloon enteroscopy in suspected Crohn's disease: a prospective study. Partha Pal, Piyush Vishwakarma, Aniruddha Pratap Singh, Palle Manohar Reddy, Mohan Ramchandani, Rupa Banerjee, Anuradha Sekaran, Polina Vijayalaxmi, Hardik Rughwani, Pradev Inavolu, Santosh Darishetty, Pradeep Rebala, Guduru Venkat Rao, Manu Tandan, D Nageshwar Reddy Published in Oct 2022, Gastrointestinal e

IBDENC ENC

Dec 21, 2022

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Edo H J Savelkoul, Pepijn W A Thomas, Lauranne A A P Derikx ,Nathan den Broeder, Tessa E H Römkens ,Frank Hoentjen Published in Nov 2022, Inflammatory bowel diseases. Abstract Background Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, and dose escalation may aid in regaining clinical benefit. This study ai

IBDENC ENC

Dec 18, 2022

Small intestinal bacterial overgrowth in patients with inflammatory bowel disease

Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study. Uday C Ghoshal , Ankur Yadav, Bushra Fatima, Anand Prakash Agrahari, Asha Misra Published in Feb 2022, INDIAN J GASTROENTEROL. Abstract Background Though small intestinal bacterial overgrowth (SIBO) is known in inflammatory bowel disease (IBD), the data on it are scanty and have limitations. Methods Data on IBD patients undergoing glucose hydrogen breath test (GHBT) were r

IBDENC ENC

Dec 16, 2022

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Gary R Lichtenstein, Brian Bressler, Carlos Francisconi, Severine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T Judd, Thomas Jones, Edward V Loftus Published: 07 November 2022 Abstract Background In patients with ulcerative colitis (UC), risks of infection and malignancies increase with age. Tofacitinib

IBDENC ENC

Dec 14, 2022

Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers

Molecular and Functional Characterization of Human Intestinal Organoids and Monolayers for Modeling Epithelial Barrier. Scott A Jelinsky, Merel Derksen, Eric Bauman, Carla S Verissimo, Wies T M van Dooremalen, Jamie Lee Roos, Celia Higuera Barón, Celia Caballero-Franco, Bryce G Johnson, Michelle G Rooks, Johanna Pott, Bas Oldenburg, Robert G J Vries, Sylvia F Boj, Marion T Kasaian, Farzin Pourfarzad, Charles V Rosadini Published in Nov 2022, Inflammatory bowel diseases. Abstr

IBDENC ENC

Dec 9, 2022

Newly Diagnosed Crohn’s Disease Patients in India and Israel Display Distinct Presentations

Newly Diagnosed Crohn’s Disease Patients in India and Israel Display Distinct Presentations and Serological Markers: Insights from Prospective Cohorts. Idan Goren ,Tali Sharar Fischler ,Henit Yanai ORCID,Partha Pal ORCID, Bhargavi Adigopula ,Sushmitha Pendyala ,Girish Ganesh ,Ravikanth Vishnubhotla ,Keren Masha Rabinowitz ,Efrat Shaham Barda ,Durga Yadamreddy ,Lihi Godny ORCID, Noam Peleg, Rupa Banerjee and Iris Dotan, on behalf of the Indo-Israeli IBD GastroEnterology Partne

IBDENC ENC

Dec 3, 2022

Genetic variants involved in innate immunity modulate the risk of inflammatory bowel diseases

Genetic variants involved in innate immunity modulate the risk of inflammatory bowel diseases in an understudied Malaysian population. Laurence Don Wai Luu, Georgia Popple, Samuel Pok Wei Tsang, Karla Vinasco, Ida Hilmi , Ruey Terng Ng, Kee Seang Chew, Shin Yee Wong, Stephen Riordan, Way Seah Lee, Hazel M Mitchell, Nadeem O Kaakoush, Natalia Castaño-Rodríguez Published in Feb 2022, Journal of gastroenterology and hepatology. Abstract Background and aim Inflammatory bowel dise

IBDENC ENC

Dec 2, 2022

Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases

Catherine Robbe Masselot, Camille Cordier, PharmD, Benjamin Marsac, Maria Nachury, Renaud Léonard, Boualem Sendid Published: 25 November 2022 Summary For the first time, fecal mucins of Crohn’s disease patients were analyzed by mass spectrometry. Compared with control subjects, Crohn’s disease patients showed a significant decrease in sialylated glycans that we propose as new noninvasive tool for screening of intestinal diseases. Discussion Currently, the accurate diagnosis o

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery